Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcomes of curative radiotherapy in patients with vulvar cancer: results of the retrospective KROG 1203 study

  • Kim, Youngkyong (Proton Therapy Center, National Cancer Center) ;
  • Kim, Joo-Young (Proton Therapy Center, National Cancer Center) ;
  • Kim, Ja Young (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Nam Kwon (Department of Radiation Oncology, Korea University Medical Center, Korea University College of Medicine) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Yong Bae (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim, Young Seok (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Juree (Department of Radiation Oncology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine) ;
  • Kim, Yeon-Sil (Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Yang, Dae Sik (Department of Radiation Oncology, Korea University Medical Center, Korea University College of Medicine) ;
  • Kim, Yeon-Joo (Proton Therapy Center, National Cancer Center)
  • Received : 2015.05.22
  • Accepted : 2015.08.24
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and Methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ${\geq}3$ cm predicted a poor prognostic factor for DFS (p = 0.040) and age (${\geq}70years$) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ${\geq}3$ cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ${\geq}70years$.

Keywords

References

  1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
  2. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol 2008;108:577-83. https://doi.org/10.1016/j.ygyno.2007.11.011
  3. Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991;164:997-1003. https://doi.org/10.1016/0002-9378(91)90573-A
  4. Bell JG, Lea JS, Reid GC. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol 2000;77:314-8. https://doi.org/10.1006/gyno.2000.5790
  5. De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma: the price of less radical surgery. Cancer 2002;95:2331-8. https://doi.org/10.1002/cncr.10969
  6. Kirby TO, Rocconi RP, Numnum TM, et al. Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol 2005;98:309-12. https://doi.org/10.1016/j.ygyno.2005.05.011
  7. Andersen BL, Hacker NF. Psychosexual adjustment after vulvar surgery. Obstet Gynecol 1983;62:457-62.
  8. Gould N, Kamelle S, Tillmanns T, et al. Predictors of complications after inguinal lymphadenectomy. Gynecol Oncol 2001;82:329-32. https://doi.org/10.1006/gyno.2001.6266
  9. Lin JY, DuBeshter B, Angel C, Dvoretsky PM. Morbidity and recurrence with modifications of radical vulvectomy and groin dissection. Gynecol Oncol 1992;47:80-6. https://doi.org/10.1016/0090-8258(92)90081-S
  10. Hoffman MS. Squamous-cell carcinoma of the vulva: locally advanced disease. Best Pract Res Clin Obstet Gynaecol 2003;17:635-47. https://doi.org/10.1016/S1521-6934(03)00051-8
  11. Han SC, Kim DH, Higgins SA, Carcangiu ML, Kacinski BM. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2000;47:1235-44. https://doi.org/10.1016/S0360-3016(00)00569-1
  12. Lee J, Kim SH, Kim G, et al. Treatment outcome in patients with vulvar cancer: comparison of concurrent radiotherapy to postoperative radiotherapy. Radiat Oncol J 2012;30:20-6. https://doi.org/10.3857/roj.2012.30.1.20
  13. Tans L, Ansink AC, van Rooij PH, Kleijnen C, Mens JW. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 2011;34:22-6. https://doi.org/10.1097/COC.0b013e3181cae6a1
  14. Landrum LM, Skaggs V, Gould N, Walker JL, McMeekin DS. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol 2008;108:584-90. https://doi.org/10.1016/j.ygyno.2007.11.010
  15. Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012;124: 529-33. https://doi.org/10.1016/j.ygyno.2011.11.003
  16. Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:79-85. https://doi.org/10.1016/S0360-3016(98)00193-X
  17. Woelber L, Trillsch F, Kock L, et al. Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 2013;5:183-92. https://doi.org/10.1177/1758834012471699
  18. National Cancer Institute (US). Common terminology criteria for adverse events (CTCAE) version 4.0. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2009.
  19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6. https://doi.org/10.1016/0360-3016(95)00060-C
  20. Beriwal S, Heron DE, Kim H, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys 2006;64:1395-400. https://doi.org/10.1016/j.ijrobp.2005.11.007
  21. Beriwal S, Coon D, Heron DE, et al. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. Gynecol Oncol 2008;109:291-5. https://doi.org/10.1016/j.ygyno.2007.10.026
  22. Canavan TP, Cohen D. Vulvar cancer. Am Fam Physician 2002;66:1269-74.
  23. Madeleine MM, Daling JR, Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-23. https://doi.org/10.1093/jnci/89.20.1516
  24. Alonso I, Fuste V, del Pino M, et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol Oncol 2011;122:509-14. https://doi.org/10.1016/j.ygyno.2011.05.016
  25. Pinto AP, Schlecht NF, Pintos J, et al. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol 2004;92:856-65. https://doi.org/10.1016/j.ygyno.2003.11.052
  26. Oh D, Huh SJ. Insufficiency fracture after radiation therapy. Radiat Oncol J 2014;32:213-20. https://doi.org/10.3857/roj.2014.32.4.213

Cited by

  1. Does HPV status influence survival after vulvar cancer? vol.142, pp.6, 2015, https://doi.org/10.1002/ijc.31139
  2. Prevalence of human papillomavirus and its prognostic value in vulvar cancer: A systematic review and meta-analysis vol.13, pp.9, 2015, https://doi.org/10.1371/journal.pone.0204162
  3. Overexpression of p16INK4a Serves as Prognostic Marker in Squamous Cell Vulvar Cancer Patients Treated With Radiotherapy Irrespective of HPV-Status vol.9, pp.None, 2015, https://doi.org/10.3389/fonc.2019.00891
  4. Lichen Sclerosis is Associated With a High Rate of Local Failure After Radio(chemo)therapy for Vulvar Cancer vol.34, pp.1, 2015, https://doi.org/10.1016/j.clon.2021.07.014